These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8519659)

  • 1. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
    Houlbrook S; Addison CM; Davies SL; Carmichael J; Stratford IJ; Harris AL; Hickson ID
    Br J Cancer; 1995 Dec; 72(6):1454-61. PubMed ID: 8519659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.
    Houlbrook S; Harris AL; Carmichael J; Stratford IJ
    Anticancer Res; 1996; 16(4A):1603-10. PubMed ID: 8712677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
    Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
    Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs acting on the beta isoform of human topoisomerase II (p180).
    Gatto B; Leo E
    Curr Med Chem Anticancer Agents; 2003 May; 3(3):173-85. PubMed ID: 12769776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
    Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
    Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.
    Sandri MI; Hochhauser D; Ayton P; Camplejohn RC; Whitehouse R; Turley H; Gatter K; Hickson ID; Harris AL
    Br J Cancer; 1996 Jun; 73(12):1518-24. PubMed ID: 8664122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
    Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta.
    Marsh KL; Willmore E; Tinelli S; Cornarotti M; Meczes EL; Capranico G; Fisher LM; Austin CA
    Biochem Pharmacol; 1996 Dec; 52(11):1675-85. PubMed ID: 8986129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
    Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
    Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
    Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
    Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
    Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.